Clinical studyPrimary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine☆
References (35)
- et al.
Melphalan and prednisone: an effective combination for the treatment of multiple myeloma
Am J Med
(1973) - et al.
Treatment of “primary” renal amyloidosis with melphalan
Lancet
(1972) - et al.
Amyloidosis of the AL type: clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone
Am J Med
(1979) - et al.
Primary amyloidosis and acute leukemia associated with melphalan therapy
Blood
(1974) - et al.
Objective response in amyloidosis treated with intermittent chemotherapy
South Med J
(1984) - et al.
Familial Mediterranean fever: a survey of 470 cases and review of the literature
Am J Med
(1967) Colchicine for familial Mediterranean fever (letter)
N Engl J Med
(1972)- et al.
Amyloidosis: review of 236 cases
Medicine (Baltimore)
(1975) - et al.
Amyloidosis (AL): clinical and laboratory features in 229 cases
Mayo Clin Proc
(1983) - et al.
Multiple myeloma I. The pathogenesis of “amyloidosis”
Semin Hematol
(1964)
Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses
Science
Structural identity of Bence Jones and amyloid fibril proteins in a patient with plasma cell dyscrasia and amyloidosis
J Clin Invest
Classification of amyloid: 1979–1980
Arthritis Rheum
“Primary” systemic amyloidosis and myeloma: discussion of relationship and review of 81 cases
Arch Intern Med
Resolution of primary amyloidosis during chemotherapy: studies in a patient with nephrotic syndrome
Ann Intern Med
Improvement in amyloidosis (letter)
Ann Intern Med
Therapy of primary amyloidosis with melphalan and prednisone
Arch Intern Med
Cited by (148)
Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update
2021, Mayo Clinic ProceedingsCitation Excerpt :Grade of Recommendation: A No trials have specifically addressed this point, but it is known through randomized trials that patients with AL treated with anti–plasma cell therapy live longer and can have clinical improvement compared with those who receive either no therapy or ineffective therapy like colchicine.85-88 Those patients who have monoclonal gammopathy of undetermined significance or smoldering myeloma with an incidental finding of a positive Congo red reaction of the bone marrow do not require therapy and have low risk of progression to vital organ involvement.
A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry–Verified Typing
2019, Mayo Clinic ProceedingsTreatment of Immunoglobulin Light Chain Amyloidosis Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement
2015, Mayo Clinic ProceedingsCitation Excerpt :Treatment should be initiated immediately in virtually all patients with systemic AL amyloidosis. No trials have been performed specifically to address this point, but it is known through randomized trials that patients with AL amyloidosis treated with chemotherapy live longer and can have clinical improvement compared with those who receive no therapy or ineffective therapy, such as colchicine.83-86 Patients who have monoclonal gammopathy of undetermined significance or asymptomatic myeloma with an incidental finding of a positive Congo red of the bone marrow do not require immediate chemotherapy.
What do I need to know about immunoglobulin light chain (AL) amyloidosis?
2012, Blood ReviewsNeurological complications in plasma cell dyscrasias
2012, Handbook of Clinical Neurology
- ☆
This work was supported in part by Research Grant CA-16835 from the National Institutes of Health, Public Health Service, Bethesda, Maryland, and by the Toor Myeloma Research Fund, West Palm Beach, Florida.